ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 16 No. 2 (2023), LYMPHOID TUMORS
Vol. 16 No. 2 (2023)
LYMPHOID TUMORS

Long-Term Results of Classical Hodgkin’s Lymphoma Treatment in Real-World Clinical Practice: Experience of Novosibirsk Hematological Unit

Published 20.02.2024
Mariya Sergeevna Voitko
Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation 630091; Municipal Clinical Hospital No. 2, 21 Polzunova ul., Novosibirsk, Russian Federation 630051
T.I. Pospelova
Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation 630091; Municipal Clinical Hospital No. 2, 21 Polzunova ul., Novosibirsk, Russian Federation 630051
I.N. Nechunaeva
Municipal Clinical Hospital No. 2, 21 Polzunova ul., Novosibirsk, Russian Federation 630051
Ya.Yu. Shebunyaeva
Novosibirsk State Medical University, 52 Krasnyi pr-t, Novosibirsk, Russian Federation 630091
2023-2
PDF_2023-16-2_192-199 (Russian)

Keywords

classical Hodgkin’s lymphoma
overall survival
progression-free survival
immediate and long-term treatment results

How to Cite

Voitko M.S., Pospelova T.I., Nechunaeva I.N., Shebunyaeva Y.Y. Long-Term Results of Classical Hodgkin’s Lymphoma Treatment in Real-World Clinical Practice: Experience of Novosibirsk Hematological Unit. Clinical Oncohematology. 2024;(2):192–199. doi:10.21320/2500-2139-2023-16-2-192-199.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Keywords

Abstract

Aim. To assess the long-term results of classical Hodgkin’s lymphoma (cHL) treatment in Novosibirsk in real-world clinical practice.

Materials & Methods. The study enrolled 408 cHL patients treated and followed-up at the hematological unit of the Novosibirsk Municipal Clinical Hospital No. 2 from January 2008 to December 2021. The median age of patients was 33 years (range 26–44 years). Among them 223 (54.7 %) female and 185 (45.3 %) male patients. There were more patients with cHL stages III (n = 103; 25.2 %) and IV (n = 120; 29.4 %) than with stage II, which was identified in 185 (45.4 %) patients. ABVD regimen was administered to 132 (32.3 %) patients, 47 (11.5 %) patients received ABVD escalated to BEACOPP. BEACOPP therapy was performed in 229 (56.2 %) patients. Subsequent radiotherapy was assigned to 202 (49.5 %) patients. Second-line therapy was required by 89 (21.8 %) patients with relapsed and resistant cHL.

Results. The 10-year overall survival (OS) was 81 %, and the 5-year OS was 91 %. Similar progression-free survival (PFS) rates were 86 % and 77 %, respectively. The 10-year PFS in patients with stage II was 87 %, while in patients with stages II (mediastinal bulky mass), III and IV, it was only 69 % (p = 0.002). The 10-year OS in patients with localized stages was 91 %, and in patients with generalized stages it was 79 % (p = 0.0006). The 10-year OS in patients less than 45 years of age was 88 %, and in patients more than 45 years of age it was 69 %. The 10-year PFS in patients less than 45 years of age was 84 %, and in the older age group it was 60 % (p = 0.001).

Conclusion. The study results demonstrate high rates of long-term survival of cHL patients and are well comparable with the data of other study groups. Nevertheless, scientific research should be continued to develop optimal risk-adapted programs of cHL chemotherapy and to define further prospects for improving the treatment outcomes of this malignant tumor.

PDF_2023-16-2_192-199 (Russian)

References

  1. Демина Е.А. Руководство по лечению лимфомы Ходжкина. М.: ГРУППА РЕМЕДИУМ, 2021.
  2. [Demina EA. Rukovodstvo po lecheniyu limfomy Khodzhkina. (Guidelines for Hodgkin’s lymphoma treatment.) Moscow: GRUPPA REMEDIUM Publ.; 2021. (In Russ)]
  3. Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–32. doi: 10.3322/caac.21438.
  4. Kaseb H, Babiker H. Hodgkin Lymphoma. Treasure Island (FL): StatPearls Publishing LLC; 2020.
  5. Salati M, Cesaretti M, Macchia M, et al. Epidemiological overview of Hodgkin lymphoma across the Mediterranean basin. Mediterr J Hematol Infect Dis. 2014;6(1):e2014048. doi: 10.4084/MJHID.2014.048.
  6. Jetley S, Khetrapal S, Pujani M, et al. Unusual histology in Hodgkin’s Lymphoma: report of an interesting case. Indian J Surg Oncol. 2017;8(2):181–4. doi: 10.1007/s13193-016-0602-5.
  7. MacLennan KA, Bennett MH, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin’s disease. A study of 1659 patients. Cancer. 1989;64(8):1686–93. doi: 10.1002/1097-0142(19891015)64:8<1686::aid-cncr2820640822>3.0.co;2-i.
  8. Szychot E, Shankar A, Haider А, Ramsay A. Variant histology nodular lymphocyte predominant Hodgkin lymphoma – a route to transformation? Br J Haematol. 2018;181(3):403–6. doi: 10.1111/bjh.14607.
  9. Dominguez RA, Alfaro LJ, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clin Transl Oncol. 2015;17(12):1005–13. doi: 10.1007/s12094-015-1429-1.
  10. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М.: Буки Веди, 2018. 324 с.
  11. [Poddubnaya IV, Savchenko VG, eds. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniyu limfoproliferativnykh zabolevanii. (Russian clinical guidelines on diagnosis and treatment of lymphoproliferative disorders.) Moscow: Buki Vedi Publ.; 2018. 324 р. (In Russ)]
  12. Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet. 2021;398(10310):1518–27. doi: 10.1016/S0140-6736(20)32207-8.
  13. Shamoon RP, Ali MD, Shabila NP. Overview and outcome of Hodgkin’s Lymphoma: Experience of a single developing country’s oncology centre. PLoS One. 2018;13(4):e0195629. doi: 10.1371/journal.pone.0195629.
  14. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol 2012;27(3):187–96. doi: 10.1007/s10654-011-9647-5.
  15. Никитин Е.А., Шаркунов Н.Н., Маркарян В.Г. и др. Диагностика и лечение лимфомы Ходжкина в практическом здравоохранении: анализ госпитального регистра городской клинической больницы им. С.П. Боткина. Онкогематология. 2016;11(3):8–19. doi: 10.17650/1818-8346-2016-11-3-8-19.
  16. [Nikitin ЕА, Sharkunov NN, Markaryan VG, et al. Treatment patterns, outcomes and long-term toxicity among patients with Hodgkin’s lymphoma in real world: results of a hospital based registry. Oncohematology. 2016;11(3):8–19. doi: 10.17650/1818-8346-2016-11-3-8-19. (In Russ)]
  17. Капланов К.Д., Волков Н.П., Клиточенко Т.Ю. и др. Результаты анализа регионального регистра пациентов с диффузной В-крупноклеточной лимфомой: факторы риска и проблемы иммунохимиотерапии. Клиническая онкогематология. 2019;12(2):154–64. doi: 10.21320/2500-2139-2019-12-2-154-164.
  18. [Kaplanov KD, Volkov NP, Klitochenko TYu, et al. Analysis Results of the Regional Registry of Patients with Diffuse Large B-cell Lymphoma: Risk Factors and Chemo-Immunotherapy Issues. Clinical oncohematology. 2019;12(2):154–64. doi: 10.21320/2500-2139-2019-12-2-154-164. (In Russ)]
  19. Мочкин Н.Е., Саржевский В.О., Дубинина Ю.Н. и др. Результаты лечения классической лимфомы Ходжкина, включающего высокодозную химиотерапию с трансплантацией аутологичных гемопоэтических стволовых клеток, в НМХЦ им. Н.И. Пирогова. Клиническая онкогематология. 2018;11(3):234–40. doi: 10.21320/2500-2139-2018-11-3-234-240.
  20. [Mochkin NE, Sarzhevskii VO, Dubinina YuN, et. al. Outcome of Classical Hodgkin’s Lymphoma Treatment Based on High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Experience in the NI Pirogov Russian National Medical Center of Surgery. Clinical oncohematology. 2018;11(3):234–40. doi: 10.21320/2500-2139-2018-11-3-234-240. (In Russ)]
  21. Von Treschkow B, Kreissl S, Goergen H, et al. Intensive treatment strategies in advanced stage Hodgkin’s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018;5(10):e462–e473. doi: 10.1016/S2352-3026(18)30140-6.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.